Universal flu vaccine to offer complete protection
An American research team presents a new flu vaccine that aims to offer more complete protection against influenza viruses. According to a recent study, the universal vaccine has the potential to significantly improve immune protection against influenza.
Researchers from Georgia State University report in the journal “Biomaterials” a new flu vaccine, which aims to trigger a broad immune response against influenza viruses of different lineages and thus provide lasting immune protection against influenza. influence.
Influenza B is responsible for a quarter of all clinical cases of infection
According to the research team, type B influenza viruses were responsible for about a quarter of all infectious diseases that needed to be treated in hospital in the decades before the SARS-CoV-2 coronavirus appeared.
Currently available influenza vaccines need to be adapted annually to the predominant viral strains and therefore vary in effectiveness. A vaccine that is equally effective against all influenza viruses would therefore be of great importance to public health.
Flu vaccines target changing parts of the virus
As the Georgia State University working group explains, previous flu vaccines have targeted an often evolving part of the flu virus called the head of the HA. For this reason the seasonal flu vaccine must be constantly reformulated.
To overcome this limitation, the team has now developed a vaccine that uses the preserved part of the virus to create substantial and extensive cross-protection against different flu strains.
Potential for a universal flu vaccine
“In this study, we generated structure-stabilized HA stem antigens from influenza B and fabricated bilayer protein nanoparticles as universal candidates for influenza B vaccine,” explains study lead author Dr. Baozhong Wang how the vaccine works.
“We found that protein nanoparticles layered with structure-stabilized constant antigens have the potential for a universal flu vaccine with improved immune protection and reach,” confirms the scientist.
The nanoparticle vaccine has already been successfully tested in human and mouse cell cultures. In both cases, the vaccination proved to be safe, biocompatible, biodegradable and highly immunogenic.
Nano-particle vaccine against influenza A and B in the design phase
“Our next goal is to combine the influenza A nanoparticles from our previous study with the influenza B nanoparticles produced and tested here to produce a universal multivalent nanoparticle-based vaccine against influenza A and B.” Wang describes the next steps. (vb)
Information on the author and source
This text corresponds to the specifications of the specialist medical literature, medical guidelines and current studies and has been verified by medical professionals.
Graduate Publisher (FH) Volker Blasek
- Yufeng Song, Wandi Zhu, Ye Wang, et al .: Stratified protein nanoparticles containing the influenza B HA stem induced sustained cross-protection against viruses spanning both viral lineages; in: Biomaterials (2022), sciencedirect.com
- Georgia State University: Universal Influenza B Vaccine Induces Broad and Long-Lasting Protection, Biomedical Science Researchers Found (veröffentlicht: 08.07.2022), eurekalert.org
This article contains general advice only and is not to be used for self-diagnosis or treatment. It cannot replace a visit to the doctor.